Michael W. Bonney

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Michael Bonney
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Michael W. Bonney

Form 4 holding Director

BRISTOL MYERS SQUIBB CO

Security class
Common Stock, $0.10 par value
Shares / value
12,501
Estimated value
$622,300
Report date
13 Jun 2021
Price
$49.78
Ownership
Direct
Form 4 holding Director

BRISTOL MYERS SQUIBB CO

Security class
Deferred Share Units
Shares / value
9,342
Estimated value
$479,323
Report date
30 Jun 2021
Price
$51.31
Ownership
Direct
Underlying class
Common Stock, $0.10 par value
Underlying amount
Form 4 holding Director

BRISTOL MYERS SQUIBB CO

Security class
Common Stock, $0.10 par value
Shares / value
2,000
Estimated value
$99,560
Report date
13 Jun 2021
Price
$49.78
Ownership
By Trust
Form 4 holding Director

IMMUNIC, INC.

Security class
Stock Option
Shares / value
100,000
Estimated value
Report date
29 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Autolus Therapeutics plc

Security class
Share Option (Right to Buy)
Shares / value
47,500
Estimated value
Report date
29 Jun 2026
Price
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
Form 4 holding Director

Autolus Therapeutics plc

Security class
Restricted Share Units
Shares / value
31,667
Estimated value
Report date
29 Jun 2026
Price
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
Form 4 holding Director

Magenta Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
18,188
Estimated value
Report date
01 Jun 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Kaleido Biosciences, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
15,000
Estimated value
Report date
30 Jun 2020
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

BRISTOL MYERS SQUIBB CO

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
13 Jun 2021
Price
$50.10
Ownership
Direct
Underlying class
Common Stock, $0.10 par value
Underlying amount

Insider Reports Filed by Michael W. Bonney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .